ABSTRACT
Background Current research does not provide a clear explanation for why some patients with Parkinson’s Disease (PD) develop psychotic symptoms. In the field of schizophrenia research the ‘aberrant salience hypothesis’ of psychosis has been influential. According to the theory, dopaminergic dysregulation leads to the inappropriate attribution of salience to otherwise irrelevant or non-informative stimuli, allowing for the formation of hallucinations and delusions. This theory has not yet been extensively investigated in the context of psychosis in PD.
Methods We investigated salience processing in 14 PD patients with a history of psychotic symptoms, 23 PD patients without psychotic symptoms and 19 healthy controls. All patients received dopaminergic medication. We examined emotional salience using a visual oddball fMRI paradigm (Bunzeck and Düzel, 2006) that previously has been used to investigate early stages of schizophrenia spectrum psychosis, controlling for resting cerebral blood flow as assessed with arterial spin labelling fMRI.
Results We found significant differences between patient groups in brain responses to emotional salience. PD patients with psychotic symptoms revealed senhanced brain responses in the striatum, the hippocampus and the amygdala compared to PD patients without psychotic symptoms. PD patients with psychotic symptoms also showed significant correlations between the levels of dopaminergic drugs they were taking and BOLD signalling, as well as psychotic symptom scores. Furthermore, our data provide a first indication for dysfunctional top-down processes, measured in a ‘jumping to conclusions’ bias.
Conclusion Our study suggests that enhanced signalling in the striatum, hippocampus and amygdala together with deficient top-down cognitive regulations is associated with the development of psychotic symptoms in PD which is similar to that proposed in the ‘aberrant salience hypothesis’ of psychosis in schizophrenia.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
n.a.
Funding Statement
This study was supported by a MRC Clinician Scientist [G0701911] and an Isaac Newton Trust award to G.K.M..
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosure and conflict of interest: This study was supported by a MRC Clinician Scientist [G0701911] and an Isaac Newton Trust award to G.K.M.. T.W.R. discloses consultancy with Cambridge Cognition, Unilever and Greenfield Bioventrures; he receives royalties from Cambridge Cognition, research grants from Shionogi & Co and GlaxoSmithKline, and editorial honoraria from Springer Nature and Elsevier. None of these conflict with the findings reported in this manuscript. None of the other authors report any conflicts of interest.
Data Availability
Data available on request.
